| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
CD4+ count-guided interruption of antiretroviral treatment.
|
N Engl J Med
|
2006
|
22.76
|
|
2
|
Effect of early versus deferred antiretroviral therapy for HIV on survival.
|
N Engl J Med
|
2009
|
19.90
|
|
3
|
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.
|
PLoS Med
|
2008
|
13.72
|
|
4
|
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.
|
J Infect Dis
|
2008
|
6.73
|
|
5
|
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.
|
JAMA
|
2000
|
6.49
|
|
6
|
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.
|
Ann Intern Med
|
2008
|
3.68
|
|
7
|
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.
|
J Infect Dis
|
2008
|
3.35
|
|
8
|
Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial.
|
Antivir Ther
|
2008
|
2.93
|
|
9
|
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.
|
AIDS
|
2008
|
2.72
|
|
10
|
Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection.
|
J Acquir Immune Defic Syndr
|
2011
|
2.21
|
|
11
|
Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.
|
J Infect Dis
|
2009
|
2.20
|
|
12
|
AIDS across Europe, 1994-98: the EuroSIDA study.
|
Lancet
|
2000
|
2.13
|
|
13
|
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study.
|
Clin Infect Dis
|
2008
|
2.06
|
|
14
|
Immune restoration with antiretroviral therapies: implications for clinical management.
|
JAMA
|
2000
|
1.99
|
|
15
|
Continuous antiretroviral therapy decreases bone mineral density.
|
AIDS
|
2009
|
1.96
|
|
16
|
Lipoprotein particle subclasses, cardiovascular disease and HIV infection.
|
Atherosclerosis
|
2009
|
1.66
|
|
17
|
Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.
|
AIDS
|
2008
|
1.34
|
|
18
|
Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.
|
J Am Heart Assoc
|
2014
|
1.26
|
|
19
|
Interruption of antiretroviral therapy is associated with increased plasma cystatin C.
|
AIDS
|
2009
|
1.26
|
|
20
|
Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption.
|
Am J Respir Crit Care Med
|
2008
|
1.21
|
|
21
|
Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults.
|
PLoS One
|
2012
|
1.16
|
|
22
|
Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study.
|
AIDS
|
2000
|
1.10
|
|
23
|
Lessons learned: Infrastructure development and financial management for large, publicly funded, international trials.
|
Clin Trials
|
2016
|
1.06
|
|
24
|
HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation.
|
J Am Heart Assoc
|
2013
|
1.04
|
|
25
|
The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life.
|
J Acquir Immune Defic Syndr
|
2008
|
1.04
|
|
26
|
Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy.
|
J Bone Miner Res
|
2013
|
1.03
|
|
27
|
Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy.
|
AIDS
|
2011
|
1.01
|
|
28
|
Asymptomatic myocardial ischaemia in HIV-infected adults.
|
AIDS
|
2008
|
1.00
|
|
29
|
Factors Associated With Plasma IL-6 Levels During HIV Infection.
|
J Infect Dis
|
2015
|
0.95
|
|
30
|
Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption.
|
AIDS
|
2010
|
0.92
|
|
31
|
N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients.
|
AIDS
|
2011
|
0.91
|
|
32
|
Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals.
|
HIV Med
|
2013
|
0.90
|
|
33
|
Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy.
|
PLoS One
|
2016
|
0.89
|
|
34
|
Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2010
|
0.89
|
|
35
|
The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters.
|
AIDS
|
2010
|
0.89
|
|
36
|
Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41.
|
AIDS Res Hum Retroviruses
|
2014
|
0.87
|
|
37
|
HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction.
|
J Acquir Immune Defic Syndr
|
2012
|
0.86
|
|
38
|
Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.
|
PLoS One
|
2013
|
0.86
|
|
39
|
Factors associated with D-dimer levels in HIV-infected individuals.
|
PLoS One
|
2014
|
0.84
|
|
40
|
Platelet count kinetics following interruption of antiretroviral treatment.
|
AIDS
|
2013
|
0.83
|
|
41
|
Haemoglobin and anaemia in the SMART study.
|
Antivir Ther
|
2011
|
0.82
|
|
42
|
Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection.
|
J Infect Dis
|
2016
|
0.82
|
|
43
|
Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies.
|
J Infect Dis
|
2002
|
0.82
|
|
44
|
Electrocardiographic spatial QRS-T angle and incident cardiovascular disease in HIV-infected patients (from the Strategies for the Management of Antiretroviral Therapy [SMART] study).
|
Am J Cardiol
|
2012
|
0.81
|
|
45
|
Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks.
|
AIDS
|
2015
|
0.79
|
|
46
|
Biomarkers and electrocardiographic evidence of myocardial ischemia in patients with human immunodeficiency virus infection.
|
Am J Cardiol
|
2012
|
0.77
|
|
47
|
Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study.
|
PLoS One
|
2015
|
0.75
|
|
48
|
Polyphenolic Composition of Crataegus monogyna Jacq.: From Chemistry to Medical Applications.
|
Nutrients
|
2015
|
0.75
|